Top of this page
Skip navigation, go straight to the content

Our Company

Our company

UCB is a global biopharmaceutical company, with a focus on neurology and immunology.

Our business is strong. Total revenue grew to €4.5 billion in 2017. We are more than 7,500 people in all four corners of the globe, inspired by patients and driven by science.

Looking ahead, we have a solid platform for continuous growth with our core products Cimzia®, Vimpat®, Neupro®, Keppra® and Briviact®, and we are preparing the launch of a potential medicine to help patients with osteoporosis. At the same time, we are very excited about the progress in our early research pipeline.

Our vision

 
image description

UCB’s ambition is to transform the lives of people living with severe diseases. We focus on neurology and immunology disorders – putting patients at the center of our world. We are Inspired by Patients. Driven by Science.

We listen. Our medicines treat thousands of people around the world and we are engaging with patients, their families and healthcare professionals to address their unmet needs.

We want to enhance our understanding of disease and the real-life experiences of patients so that our teams are able to deliver the right drug and the right care to the right patient.

UCB is continuously working to advance science and embrace new knowledge. We are leveraging scientific advances and skills in areas such as genetics, biomarkers and human biology. Patients inspire us to bring them value through cutting-edge science, innovative drugs, and practical solutions – so that they and their carers can get on with their lives.

Our strategy

We recognise that radical changes are taking place in the eco-system of care and that we need to evolve accordingly to deliver on our vision. The key element of our evolution is to focus on the delivery of increased patient value.

There is no such thing as an “average patient”. We want to use all the tools, channels and scientific advances at our disposal to develop a better understanding of the various expressions of a disease and embed the real needs of specific patient populations in our science and innovation process.

That is why we support patient groups who provide valuable services to patient communities and understand what matters to people living with severe diseases.

We believe in partnership. Our scientists collaborate with leading researchers from academia and industry to advance science and deliver the solutions patients need. Our open approach to innovation equips us to meet today’s biggest healthcare challenges.

 
image description
 

Corporate brochure

image description